Helen Tomkinson

603 total citations
40 papers, 447 citations indexed

About

Helen Tomkinson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Helen Tomkinson has authored 40 papers receiving a total of 447 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 16 papers in Molecular Biology and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Helen Tomkinson's work include Lung Cancer Treatments and Mutations (14 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Helen Tomkinson is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), PI3K/AKT/mTOR signaling in cancer (7 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Helen Tomkinson collaborates with scholars based in United Kingdom, United States and Poland. Helen Tomkinson's co-authors include Nidal Al‐Huniti, Eric Masson, Kirill Peskov, Lulu Chu, Gabriel Helmlinger, Karthick Vishwanathan, Donald R. Stanski, Veronika Voronova, Yuri Kosinsky and Simon J. Dovedi and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Helen Tomkinson

38 papers receiving 434 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Helen Tomkinson United Kingdom	13	178	144	105	62	61	40	447
Cynthia M. Nijenhuis Netherlands	14	202 1.1×	172 1.2×	107 1.0×	105 1.7×	113 1.9×	28	535
Anshu Marathe United States	11	203 1.1×	183 1.3×	112 1.1×	25 0.4×	29 0.5×	22	559
Noelia Nebot United States	11	164 0.9×	180 1.3×	62 0.6×	94 1.5×	55 0.9×	17	432
Stéphanie van Hoppe Netherlands	12	257 1.4×	148 1.0×	73 0.7×	91 1.5×	42 0.7×	15	449
Devron R. Shah United Kingdom	7	241 1.4×	190 1.3×	187 1.8×	48 0.8×	95 1.6×	8	599
Johannes J.M. Rood Netherlands	11	108 0.6×	195 1.4×	88 0.8×	127 2.0×	83 1.4×	16	360
Niels de Vries Netherlands	12	264 1.5×	155 1.1×	113 1.1×	69 1.1×	58 1.0×	21	459
Herbert Birnboeck Switzerland	9	162 0.9×	115 0.8×	244 2.3×	56 0.9×	38 0.6×	11	654
Murray Yule United States	12	211 1.2×	335 2.3×	89 0.8×	50 0.8×	77 1.3×	31	575
Youwei Bi United States	14	275 1.5×	225 1.6×	307 2.9×	55 0.9×	19 0.3×	25	768

Countries citing papers authored by Helen Tomkinson

Since Specialization

Citations

This map shows the geographic impact of Helen Tomkinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Tomkinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Tomkinson more than expected).

Fields of papers citing papers by Helen Tomkinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Tomkinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Tomkinson. The network helps show where Helen Tomkinson may publish in the future.

Co-authorship network of co-authors of Helen Tomkinson

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Tomkinson. A scholar is included among the top collaborators of Helen Tomkinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Tomkinson. Helen Tomkinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jones, Rhys D.O., et al.. (2023). Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation–Positive, MET-Amplified Non–Small Cell Lung Cancer Model. Molecular Cancer Therapeutics. 22(5). 679–690. 4 indexed citations

Sharma, Shringi, Xavier Pépin, Jean Cheung, et al.. (2022). Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. British Journal of Clinical Pharmacology. 88(10). 4573–4584. 3 indexed citations

Vishwanathan, Karthick, Helen Wei, Huan Liu, et al.. (2021). Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies. British Journal of Clinical Pharmacology. 88(5). 2284–2296. 14 indexed citations

Tomkinson, Helen, et al.. (2021). Imputing Biomarker Status from RWE Datasets—A Comparative Study. Journal of Personalized Medicine. 11(12). 1356–1356. 1 indexed citations

Bellanti, Francesco, Huan Liu, Karthick Vishwanathan, et al.. (2021). Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach. British Journal of Clinical Pharmacology. 88(2). 846–852. 9 indexed citations

Schalkwijk, Stein, Li Zhou, Lokesh Jain, et al.. (2021). Population pharmacokinetics and exposure–response of selumetinib and its N‐desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas. Cancer Chemotherapy and Pharmacology. 88(2). 189–202. 10 indexed citations

Sharma, Shringi, Xavier Pépin, Haran Burri, et al.. (2021). New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS). Blood. 138(Supplement 1). 4365–4365. 8 indexed citations

Berges, Aliénor, et al.. (2021). QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small‐Molecule New Drug Applications Approved During 2011‐2019. The Journal of Clinical Pharmacology. 61(8). 1106–1117. 12 indexed citations

Zhou, Li, Karthick Vishwanathan, Martin Wild, et al.. (2021). Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug‐Drug Interactions and Pediatric Dose Regimens. The Journal of Clinical Pharmacology. 61(11). 1493–1504. 12 indexed citations

10.

Itoh, Y., Helen Tomkinson, Martin Johnson, et al.. (2019). Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 83(5). 849–858. 14 indexed citations

11.

Kosinsky, Yuri, Simon J. Dovedi, Kirill Peskov, et al.. (2018). Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model. Journal for ImmunoTherapy of Cancer. 6(1). 17–17. 83 indexed citations

12.

Cheung, S. Y. Amy, Joanna Parkinson, Corina Dota, et al.. (2018). A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisation. Journal of Pharmacokinetics and Pharmacodynamics. 45(3). 365–381. 5 indexed citations

13.

Masson, Eric, et al.. (2018). Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology. The Journal of Clinical Pharmacology. 59(4). 463–471. 13 indexed citations

14.

LoRusso, Patricia, Jeffrey R. Infante, Kevin B. Kim, et al.. (2017). A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors. BMC Cancer. 17(1). 173–173. 15 indexed citations

15.

Tomkinson, Helen, Eileen McBride, Paul Martin, et al.. (2017). Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects. Clinical Therapeutics. 39(11). 2260–2275.e1. 12 indexed citations

16.

Infante, Jeffrey R., Roger B. Cohen, Kevin B. Kim, et al.. (2017). A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors. Investigational New Drugs. 35(5). 576–588. 13 indexed citations

17.

Lenz, Eva M., et al.. (2011). The metabolism of [14C]-zibotentan (ZD4054) in rat, dog and human, the loss of the radiolabel and the identification of an anomalous peak, derived from the animal feed. Journal of Pharmaceutical and Biomedical Analysis. 55(3). 500–517. 11 indexed citations

18.

Tomkinson, Helen, John Kemp, Stuart Oliver, et al.. (2011). Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies. PubMed. 11(1). 3–3. 27 indexed citations

19.

Tomkinson, Helen, et al.. (2011). The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs. Xenobiotica. 41(9). 784–796. 5 indexed citations

20.

Tomkinson, Helen, et al.. (2010). An open-label, randomized, single-center, two-period, phase I, crossover study of the effect of zibotentan (ZD4054) on the pharmacokinetics of midazolam in healthy male volunteers. Clinical Therapeutics. 32(7). 1372–1386. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact